Records and redescription of a mygalomorph spider genus ignored for over 100 years with a new species: the genus Atmetochilus Simon, 1887 (Araneae Nemesiidae) in Thailand

Kunsete, Chawakorn, Sivayyapram, Varat, Traiyasut, Prapun, Thanoosing, Chawatat, Khamwan, Kitiwat, Warrit, Natapot (2020): Records and redescription of a mygalomorph spider genus ignored for over 100 years with a new species: the genus Atmetochilus Simon, 1887 (Araneae Nemesiidae) in Thailand. Zootaxa 4819 (3): 521-543, DOI: https://doi.org/10.11646/zootaxa.4819.3.

DataSheet1_Dynamic 18F-FDG-PET kinetic parameters for epileptogenic zone localization in drug-resistant epilepsy.DOCX

Objective: Precisely localizing the seizure onset zone remains a challenging task in drug-resistant epilepsy (DRE) patients especially given its critical role in successful surgery and effective management. This study aimed to investigate the kinetic parameters of regional 18F-fluorodeoxyglucose (FDG) uptake in DRE patients, aiming to identify the kinetic parameters best enabling the identification of the epileptogenic region.Methods: Consecutive DRE patients with clinically mandated interictal 18F-FDG PET/CT were recruited from October 2019 to September 2020 for pre-surgical evaluation. Immediately after injecting 18F-FDG of 112–179 MBq, dynamic data were acquired for 90 min. The motion correction and resampling to the Montreal atlas was performed in order to generate a transformation matrix. 116 volume of interests (VOIs) and regional time-activity curves (TACs) were generated by employing the automated anatomical labeling (AAL) template using PMOD software. Kinetic parameters of FDG unidirectional blood-brain clearance (K1), efflux (k2), phosphorylation (k3), and net metabolic flux (Ki) were derived using irreversible 2-tissue-compartment model with an image-derived input function (IDIF). The kinetic parameters values obtained from all regions were ranked and compared with the presumed epileptogenic zone (EZ).Results: Eleven DRE patients (5 males, 6 females, mean age 35.1 ± 10.2 years) were analyzed. We found that the region with the lowest values of Ki provided correct lateralization in 7/7 (100%) of patient with temporal lobe epilepsy (TLE) and the region with the lowest Ki and k3 parameters showed concordance with the EZ in 100% and 71.4% of patients, respectively.Conclusion: The present parametric approach to the evaluation of FDG-PET may be more sensitive than semi-quantitative approaches for the detection of pathophysiology in the EZ of patients with medically unresponsive TLE in addition to the routine clinical investigations.</p

Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Background: Absorbed dose estimates for pediatric patients require pharmacokinetics that are, to the extent possible, age-specific. Such age-specific pharmacokinetic data are lacking for many of the diagnostic agents typically used in pediatric imaging. We have developed a pharmacokinetic model of [18F]fluorodeoxyglucose (FDG) applicable to premature infants and to 0- (newborns) to 5-year-old patients, which may be used to generate model-derived time-integrated activity coefficients and absorbed dose calculations for these patients. Methods: The FDG compartmental model developed by Hays and Segall for adults was fitted to published data from infants and also to a retrospective data set collected at the Boston Children’s Hospital (BCH). The BCH data set was also used to examine the relationship between uptake of FDG in different organs and patient weight or age. Results: Substantial changes in the structure of the FDG model were required to fit the pediatric data. Fitted rate constants and fractional blood volumes were reduced relative to the adult values. Conclusions: The pharmacokinetic models developed differ substantially from adult pharmacokinetic (PK) models which can have considerable impact on the dosimetric models for pediatric patients. This approach may be used as a model for estimating dosimetry in children from other radiopharmaceuticals. Electronic supplementary material The online version of this article (doi:10.1186/s13550-016-0179-6) contains supplementary material, which is available to authorized users

Additional file 1: of Pharmacokinetic modeling of [18F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds

Pharmacokinetic model equations for premature infants and newborn through 5-year-olds. Equations from SAAM II compartment model used to derive TIAC in each source tissue (or sample) for brain, lungs, heart wall, kidneys, and liver are also provided. For each source organ or each sample, qi represents the differential equations created internally and solved by SAAM II. (DOCX 290 kb